Virus SARS-CoV-2 S protein (944-1214 aa) Monoclonal antibody, PBS Only
SARS-CoV-2 S protein (944-1214 aa) Monoclonal Antibody for WB, Indirect ELISA
Host / Isotype
Mouse / IgG1
Reactivity
Virus
Applications
WB, Indirect ELISA
Conjugate
Unconjugated
CloneNo.
1H5E6
验证数据展示
产品信息
67794-1-PBS targets SARS-CoV-2 S protein (944-1214 aa) in WB, Indirect ELISA applications and shows reactivity with Virus samples.
Tested Applications | WB, Indirect ELISA Application Description |
Tested Reactivity | Virus |
Immunogen | SARS-CoV-2 S protein (944-1214 aa) fusion protein Ag30682 种属同源性预测 |
Host / Isotype | Mouse / IgG1 |
Class | Monoclonal |
Type | Antibody |
Full Name | SARS-CoV-2 Spike Protein |
Synonyms | S protein, SARS-CoV-2 Spike Glycoprotein, SARS-CoV-2 Spike Glycoprotein (944-1214 aa), spike, spike protein |
Calculated Molecular Weight | 141 kDa |
GenBank Accession Number | NC_045512 |
Gene Symbol | SARS-COV-2 |
Gene ID (NCBI) | 43740568 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
Storage Buffer | PBS Only |
Storage Conditions | Store at -80°C. The product is shipped with ice packs. Upon receipt, store it immediately at -80°C |
背景介绍
Coronaviruses (CoVs) infect human and animals and cause varieties of diseases, including respiratory, enteric, renal, and neurological diseases. CoV uses its spike protein to recognize ACE2 as its receptors and mediate membrane fusion and virus entry into host cells(PMID: 32221306). Each monomer of trimeric S protein is about 180 kDa, and contains two subunits, S1 and S2,S1 recognizes and binds to host receptors, and subsequent conformational changes in S2 facilitate fusion between the viral envelope and the host cell membrane(PMID: 19198616). Although the amino acid sequences of the S-glycoprotein were found to be different between the various HCoV, the structures showed high similarity, but the best 3D structural overlap shared by SARS-CoV and SARS-CoV-2, consistent with the shared ACE2 predicted receptor (PMID: 32522207). The spike protein of CoVs can be a target for vaccine and therapeutic development (PMID: 19198616).